ICON Wins ‘Partnership Pioneers of the Year’ Award in Recognition of Global Partnership with Pfizer
2013年4月24日 - 7:00PM
ビジネスワイヤ(英語)
ICON plc, (NASDAQ: ICLR) a global provider of
outsourced development services to the pharmaceutical,
biotechnology and medical device industries, today announced that
is has received the 2013 “Partnership Pioneers of the Year” award
in recognition of its strategic partnership with Pfizer and
PAREXEL.
Presented by the Institute for International Research and
Partnerships in Clinical Trials’ advisory board, the award
recognises two or more companies engaged in a partnership that
moves beyond the traditional transactional model to a more
strategic approach that can bring innovation to the drug
development process.
ICON was selected by Pfizer in May 2011 as one of two strategic
partners for global clinical research and development. The
partnership was part of Pfizer’s comprehensive program of change in
R&D to sharpen research focus, deliver differentiated
innovation, and create a more flexible cost base through external
partnerships for certain R&D services.
Commenting on the award, ICON’s CEO, Mr. Ciaran Murray, said: “I
am delighted that ICON has received this award which recognises our
commitment to the strategic collaboration with Pfizer. Using our
scale, clinical experience, and technology such as Firecrest, we
are able to deliver high-quality solutions for the Pfizer
partnership. These solutions help reduce cycle times and cost and
improve the quality and productivity of drug development. Over the
past two years we have worked hard with Pfizer to transform their
drug development model and have built a solid platform that will
support the continued success and evolution of the partnership in
the future.”
“Our new Alliance Partner Model is providing a solid foundation
for integrated quality clinical services,” said Dr. John Hubbard,
SVP of Development Operations for Pfizer. “ICON and PAREXEL’s
clinical expertise and innovative technology continues to set the
standard for best practice, this award recognises progress toward
our goal of creating a common culture dedicated to universally
improving clinical trial implementation. We look forward to
deepening our relationship with ICON and PAREXEL, to achieve our
partnership’s full potential, and ultimately deliver medicines to
patients in need more quickly and efficiently.”
Pfizer, ICON and PAREXEL accepted the honour during an awards
ceremony at the 22nd annual Partnerships in Clinical Trials
conference.
The statements made in this press release may contain
forward-looking statements that involve a number of risks and
uncertainties. A description of risks and uncertainties relating to
ICON and its business can be found in Forms 20-F for the fiscal
year ended December 31st 2012 and in the other forms filed with the
US Securities and Exchange Commission, including the F-1, S-8 and
F-3. ICON disclaims any intent or obligation to update these
forward-looking statements.
Notes to Editors
About ICON plc
ICON plc is a global provider of outsourced development services
to the pharmaceutical, biotechnology and medical device industries.
The company specialises in the strategic development, management
and analysis of programs that support clinical development - from
compound selection to Phase I-IV clinical studies. ICON currently
has approximately 10,045 employees, operating from 79 locations in
37 countries.
Further information is available at www.iconplc.com
ICON/ICLR-G
ICON (NASDAQ:ICLR)
過去 株価チャート
から 9 2024 まで 10 2024
ICON (NASDAQ:ICLR)
過去 株価チャート
から 10 2023 まで 10 2024